New immune-boosting transplant aims to stop leukemia relapse

NCT ID NCT07552649

First seen May 04, 2026 · Last updated May 16, 2026 · Updated 4 times

Summary

This study tests a stem cell transplant from a matched sibling donor combined with special immune cells (regulatory and conventional T cells) for people with high-risk acute myeloid leukemia (AML). The goal is to prevent the cancer from coming back after the transplant. About 28 participants will be enrolled, and the main measure is how many are still free of disease two years later.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOID LEUKEMIA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Azienda Ospedaliera di Perugia - Ospedale S. Maria della Misericordia

    Perugia, 06132, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Presidio Ospedaliero Pescara - Azienda Sanitaria Locale di Pescara

    Pescara, 65124, Italy

    Contact

Conditions

Explore the condition pages connected to this study.